Meta Pixel

News and Announcements

In H2 2021, TurtleTree successfully raised US$ 30,000,000 and joined forces with Solar Biotech to speed up Go-to-Market

  • Published February 11, 2022 12:00AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

Venture Capital investment has skyrocketed in precision fermentation companies over the past decade. When compared to conventional agriculture, lab-based agriculture offers numerous ethical and health benefits, reduces carbon emissions and land use. It also removes the waste associated with meat farming.

The main challenge is to improve production efficiency by developing strains that maximise yield and produce as many target proteins and sugars as possible from a given volume of liquid.

TurtleTree successfully raised US$ 30,000,000 in the first tranche of its Series-A round led by VERSO Capital in H2 2021. In addition, TurtleTree Labs has entered a new strategic partnership with Solar Biotech, an industrial biomanufacturing specialist, to scale up the process of producing cell-based milk ingredients, which is a major step towards reaching price parity with traditional food production methods. This achievement comes after TurtleTree Labs partnership with Dyadic International, a global biotechnology company focused on accelerating development and lowering production costs of numerous biological products.

TurtleTree’s journey to a new generation of nutrition that is better for the planet, better for the animals, and better for people everywhere has reached a significant turning point in 2021.

About The Company

TurtleTree is pioneering nutrition from human milk, using novel technologies including cell-based and precision fermentation to address the unsustainable cattle farming practices impacting the environment with extensive use of water use and growing emissions of greenhouse gas including carbon dioxide and methane etc…In that context, TurtleTree Labs aims at unlocking access to the natural ingredients found in human milk using a host of new technologies, making its benefits available for all.

Register Interest

Capital Insights
The System’s Immune System: Why Big Tech Will Solve What Big Pharma Can’t

The central investment thesis for the future of human health pits Big Pharma against Big Tech. This blog post explores the “Protocol Paradox” in current cancer care and argues that the convergence of hyperscalers and life-science experts—treating biology as a data and compute problem—represents the defining compounding investment opportunity of this era.

Capital Insights
Following the Billions: Where the Hyperscalers are Betting on the Future

The roadmap for the next decade isn’t hidden in pitch decks—it’s written on the balance sheets of Microsoft, Amazon, and Google. Their collective investment is flowing into three key areas: GPU Chips, AI Factories, and Energy. This foundational buildout signals a $7–$20 trillion economic convergence, where the physical race for infrastructure and energy is paramount. The article also covers the powerful macro case for digital assets in this new era.

Join over 45,000+ sophisticated investors

Join Now